REMARKS

Upon entry of the above amendment, claims 1, 3, 5, 12, 20, 21, 23, 29, 34-36 and 54 will be pending in the present invention. Applicants amended claims 1 and 37 to clarify the invention. No new matter has been added.

New Claim Objection

Applicants corrected the misspelling in the status identifier of claim 34.

Applicants amended claim 37 to replace carboxyamide with carboxamide as suggested by the Examiner.

Applicants respectfully request withdrawal of the abstract objection

New Claims rejections 35 U.S.C. §112, Second paragraph

Claims 1, 3, 5, 12, 20, 21, 23, 29, 34-36 and 54 stand rejected under 35 U.S.C. §112, second paragraph as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regards as the invention.

Applicants respectfully disagree that the phrase "(optionally) substituted" render the claims indefinite. However in order to expedite prosecution, Applicants addressed the alleged indefinitiveness of the claims with the following actions:

- Applicants amended claim 1 and introduced a list of substituents for each occurrence where substituents are desired. Support to the amendments can be found for example on page 5, line 24 to page 6 Line 5; on page 6 lines 18 to 25; on page 7 lines 18-20 and on page 10 lines 4 to 6.
- Applicants amended the definition of R³ and R¹⁰ by removing the term "substituted aikyi".

Applicants respectfully request withdrawal of the 35 U.S.C. §112, second paragraph rejection.

Conclusion

Applicants addressed each and every issue set forth by the Examiner. Applicants respectfully submit that the claims are in good condition for allowance.

If Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (617)871-5027.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc. NIBR Patents 220 Massachusetts Ave. Cambridge, MA 02139

Date: October 15, 2009

Sophie Binet Cross Reg. No. 59,494